Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Wangjun Yan
Patient-derived vascularized organoid-on-a-chip model for therapeutic response assessment in synovial sarcoma
Abstract Synovial sarcoma (SS) lacks effective therapies and physiologically relevant models that faithfully recapitulate the tumor microenvironment. Here, we established synovial sarcoma patient-derived organoids (SPDOs) that preserved the histological, genomic, and transcriptomic features of their parental tumors.
Heparin inhibits NLRP3-dependent pyroptosis in acute pancreatitis
Abstract The ameliorative effects of heparin on acute pancreatitis (AP) have received widespread attention. NLRP3 inflammasome-dependent pyroptosis has been reported to be a key factor contributing to AP development. However, it remains unclear whether heparin alleviates AP by modulating NLRP3 inflammasome-dependent pyroptosis. An AP model was established in vivo and in vitro using Sprague Dawley rats and AR42J cells. TUNEL and propidium iodide staining assessed cell death.
A pan-cancer single-cell transcriptomic atlas of human bone metastases
|
Keywords bone metastasis single-cell transcriptome atlas pan-cancer immunotherapy Introduction Bone metastases (BMs) are the most common types of bone tumors in adults. It is estimated that 65%–80% of individuals with breast or prostate cancer,1 along with 30%–60% of those with thyroid, kidney, lung, or gastrointestinal cancers,2,3 will experience BM.
By Shuoer Wang, Fen Ma, Dongliang Wang, Qian Yu, Haoyu Zheng, Ziqing Chen, Songjiao Zhao, Lun Xu, Qingrong Ye, Yiwen Tan, Wending Huang, Zhengwang Sun, Zhiqiang Wu, Meng Fang, Mo Cheng, Yingzheng Ji, Yunkui Zhang, Bingxin Gu, Shaoli Song, Yang Chen, Jiwei Zhang, Yang Shao, Wangjun Yan, Yidi Sun, Weiluo Cai
|
Cell Reports Medicine
Verified
Case Report: Metastatic benign fibrous histiocytoma: a case series and review of diagnostic and therapeutic challenge
Introduction Benign Fibrous Histiocytoma (BFH), also known as dermatofibroma, is a common mesenchymal tumor of the skin. BFH is a benign tumor arising from fibroblasts and histiocytes affecting the dermis and subcutaneous soft tissues (1). It typically presents as an isolated cutaneous nodule that is firm or cystic, skin-colored or brown, later developing into a polypoid nodule or raised plaque (2). BFH primarily affects adults and is frequently found on the extremities (3–5).
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study - Nature Communications
Abstract This was a multicenter, single-arm, open-label, phase Ib/II study (NCT04255576), aimed to evaluate the efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). JMT103 (2 mg/kg) was administered subcutaneously every four weeks, with loading doses on days 8 and 15.
Optimal timing of re‐excision in synovial sarcoma patients: Immediate intervention versus waiting for local recurrence
AJCC American Joint Committee on Cancer CT computed tomography DRFS distant relapse-free survival LR local recurrence LRFS local recurrence-free survival LRG local recurrence group MRI magnetic resonance imaging NRG no residual group OS overall survival RE re-excision RG residual group SS synovial sarcoma STS soft tissue sarcomas UPE unplanned excision 1 INTRODUCTION Synovial sarcoma (SS) is a rare and highly invasive form of soft tissue sarcoma (STS), accounting for 5%–10% of all STS cases...
A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations
1 INTRODUCTION Melanoma is an aggressive and genetically heterogenous disease. It frequently harbors BRAF, NRAS, or KIT mutations which influence both tumor development and treatment strategies. Nearly half of cutaneous melanoma and 5%–10% of other subtypes possess a BRAFV600 mutation.1-3 In the adjuvant setting, BRAF and MEK inhibitors combination has been approved for BRAFV600-mut patients with Stage III disease, while anti-PD1 monotherapy approved for both mutant and wild-type melanoma.
Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study
Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Wangjun
Contact Wangjun, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack